| Name | Title | Contact Details |
|---|
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The companys initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Enshos assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the companys pipeline.
Federal Business Council is a Annapolis Junction, MD-based company in the Business Services sector.
Brazil Information Center is a Washington, DC-based company in the Business Services sector.
QArea (BugHuntress QA Lab) is a San Jose, CA-based company in the Business Services sector.
HUK 24 is a Coburg, AK-based company in the Business Services sector.